Business Wire

Breakthrough Discovery: British Explorer Andrew ‘Sandy’ Irvine’s Partial Remains Believed to Be Found on Mount Everest After 100 Years

11.10.2024 08:00:00 CEST | Business Wire | Press release

Share

Discovery Made by Expedition Team Led by Jimmy Chin During Mount Everest Climb for Upcoming National Geographic Documentary Film, Reported Exclusively on NatGeo.comEvidence Is First Possible Proof of Irvine’s Death Since Disappearing During 1924 Expedition With George Mallory, Whose Remains Were Found on Everest in 1999 by Conrad AnkerExclusive Photos NatGeo.com Story: https://www.nationalgeographic.com/adventure/article/sandy-irvine-body-found-everest

After 100 years of speculation surrounding his fate, the partial remains of Andrew Comyn “Sandy” Irvine are believed to have finally been discovered on Mount Everest. At age 22, Irvine vanished while attempting to conquer the world’s tallest peak on June 8, 1924, along with his climbing partner, renowned mountaineer George Mallory.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241010214459/en/

A sock embroidered with "A.C. Irvine", along with a boot, has been discovered on the Central Rongbuk Glacier below the North Face of Mount Everest by a team led by Jimmy Chin. This is the first possible proof of Irvine's death since disappearing during a 1924 expedition. (credit: Jimmy Chin)

The discovery was made recently by a small team including National Geographic Explorer, photographer, Academy Award-winning director and professional climber Jimmy Chin along with climbers and filmmakers Erich Roepke and Mark Fisher. What is believed to be Irvine’s foot, encased in a sock and boot, was found on the Central Rongbuk Glacier below the North Face of Everest at a lower altitude than Mallory’s remains were located. The partial remains – identified with his name stitched into the sock – are now in the possession of the China Tibet Mountaineering Association, which is responsible for climbing permits on Everest’s northern side.

The find was reported to the Royal Geographical Society - who jointly organized Mallory and Irvine’s expedition along with the Alpine Club - which at the time was only the third British climb on Mount Everest. It was also shared with Irvine’s great niece and biographer, Julie Summers – one of many living family relatives. The Irvine family has volunteered to compare DNA test results with the remains to confirm Irvine’s identity.

“Any expedition to Everest follows in the shadow of Irvine and Mallory,” said Chin. “We certainly did. And sometimes in life the greatest discoveries occur when you aren’t even looking. This was a monumental and emotional moment for us and our entire team on the ground, and we just hope this can finally bring peace of mind to his relatives and the climbing world at large.”

“It is remarkable that this discovery was made in the centenary year of Sandy’s disappearance,” said Summers. “I have lived with this story since I was a 7-year-old when my father told us about the mystery of Uncle Sandy on Everest. The story became more real when climbers found the body of George Mallory in 1999, and I wondered if Sandy’s body would be discovered next. A quarter of a century after that discovery, it seemed extremely unlikely that anything new would be found. When Jimmy told me that he saw the name A.C. Irvine on the label on the sock inside the boot, I found myself moved to tears. It was and will remain an extraordinary and poignant moment.”

Professor Joe Smith, director of the Royal Geographical Society, said of the discovery: “As joint organiser of the 1924 Everest expedition (with the Alpine Club), the Society deeply appreciates the respect Jimmy Chin’s team has shown Sandy Irvine’s remains and their sensitivity toward Sandy’s family members and others connected to that expedition. Sandy was an exceptional figure and made a significant contribution to our understanding of Everest and the Himalaya. This discovery of his remains provides an element of closure for his relatives and the wider mountaineering community, and we are grateful to Jimmy and his team for enabling this and ensuring Sandy is in safe hands. The Society will continue to assist Jimmy, his team and Sandy’s extended family during what will inevitably be a period of intense global interest.”

Irvine and Mallory were British mountaineers who disappeared in 1924 during an expedition organized by the Royal Geographical Society and Alpine Club to be the first to summit Everest. The mystery of whether they reached the summit before their death has intrigued climbers and historians for decades. Mallory’s body was discovered in 1999 by climber Conrad Anker, but until now, Irvine’s remains had never been found.

The team’s climb was funded by National Geographic Documentary Films for an upcoming documentary directed and produced by the Academy Award- and the BAFTA Award-winning team behind “Free Solo,” E. Chai Vasarhelyi and Chin, and their banner Little Monster Films.

Irvine Family Statement on the Discovery:

“The Irvine family is deeply moved to hear of the discovery of partial remains of Sandy Irvine. We are grateful to the mountaineering and film team, led by Jimmy Chin, who made the discovery and who have treated it with respect and professionalism. We are happy that the remains are now in the hands of the CTMA. Sandy Irvine was the youngest member of the 1924 Mount Everest expedition and was lost on the upper slopes of the mountain with George Mallory when the two disappeared on 8 June 1924.”

ABOUT JIMMY CHIN

Chin is a professional climber, skier, mountaineer, 20-year member of The North Face Athlete Team and National Geographic Explorer. Consistently over the past 20 years, Chin has led or participated in cutting-edge climbing and ski mountaineering expeditions to all seven continents and participated in the first and only American ski descent from the summit of Mount Everest. He is also a filmmaker and National Geographic photographer. He has worked with many of the greatest explorers, adventurers and athletes of our time, documenting their exploits in the most challenging conditions and locations in the world. Together with his wife, Elizabeth Chai Vasarhelyi, he has co-directed the films “Meru,” “Free Solo,” “The Rescue,” “Wild Life,” “Return To Space,” and their first scripted feature, “Nyad.” Their next documentary feature, “Endurance” premieres this weekend at the BFI London Film Festival. Chin and Vasarhleyi won the Best Documentary Oscar® in 2019 for “Free Solo.”

Exclusive Photos
NatGeo.com Story:
https://www.nationalgeographic.com/adventure/article/sandy-irvine-body-found-everest

View source version on businesswire.com: https://www.businesswire.com/news/home/20241010214459/en/

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Incyte Announces Positive CHMP Opinion for Opzelura® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 13:30:00 CEST | Press release

If approved, Opzelura® (ruxolitinib) cream will be the first steroid-free, topical JAK treatment option in the European Union (EU) for adults with moderate atopic dermatitis (AD) for whom standard topical therapies have failedAD, the most common type of eczema which affects 230 million people globally,1 is a chronic, recurring, inflammatory and highly pruritic (itchy) skin condition that can have a significant impact on daily life2Phase 3 TRuE‑AD4 data supporting the positive CHMP opinion demonstrated that ruxolitinib cream met both co‑primary endpoints at Week 8, maintained disease control with as-needed treatment through Week 24 and was well tolerated3,4,5 Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids

Datroway® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 13:00:00 CEST | Press release

Recommendation based on TROPION-Breast02 phase 3 trial where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival If approved, Datroway has potential to be the first TROP2 directed antibody drug conjugate for patients in EU with a demonstrated overall survival benefit as first-line treatment Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use

DAYBU®(trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 12:49:00 CEST | Press release

-- European Commission decision expected in the coming months-- If approved, DAYBU®would become the first treatment for neurobehavioral symptoms of Rett syndrome in the European Union Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating

HTEC Showcases Lakebase Branching at Databricks’ Data & AI Summit26.6.2026 11:18:00 CEST | Press release

HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. The Solution was developed in collaboration with a leading risk and compliance technology provider who serves financial institutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260626875859/en/ HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. Solving Critical Development Bottlenecks in Regulated Environments At the core of the collaboration was a shared challenge: how to enable modern data workflows in an envi

Stallergenes Greer Named One of Switzerland’s Best Managed Companies for 202626.6.2026 10:28:00 CEST | Press release

Stallergenes Greer, a global leader in allergy care, has been recognised for its overall business performance, company culture, and sustained growth by receiving the prestigious 2026 Switzerland’s Best Managed Companies award. The 2026 Best Managed Companies programme award winners are among Switzerland’s best private companies. The awards are derived from Deloitte’s global Best Managed Companies awards programme, an internationally recognised programme that evaluates businesses based on their leadership in the areas of strategy, culture and commitment, capabilities, innovation, governance and financial performance. Applicants are evaluated by an independent jury of experts. The evaluation of the Switzerland awards is based on more than 30 years of observed practice from the global awards programme that has been rolled out in 50+ countries worldwide. This recognition reflects Stallergenes Greer's consistent ability to deliver on its strategic vision while maintaining the operational di

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye